Desmoteplase: Development discontinued

Lundbeck ceased development of desmoteplase to treat acute ischemic stroke. The compound, which has been in

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE